A 57% complete response rate in stage III unresectable NSCLC stops you cold — the current standard of care, concurrent chemoradiation plus durvalumab, produces complete responses in fewer than 5% of patients. That is the number that frames everything about the Part 1 data from CONVERGE, a J&J-sponsored randomized Phase 2 study of JNJ-1900 (NBTXR3) presented at ESTRO 2026. Seven patients completed the full treatment regimen. Four achieved complete response. Six responded. All seven had disease control. The sample is tiny, but the directional signal is not subtle.
The mechanistic logic matters here. NBTXR3 consists of hafnium oxide nanoparticles injected once directly into the tumor, then activated by radiotherapy. The physical mechanism — not a biologic, not a targeted agent — amplifies local tumor cell killing and is designed to trigger downstream adaptive immune activation. Pairing that with consolidation durvalumab is not incidental: you are stacking a radiotherapy-enhanced immunogenic kill with a checkpoint that prolongs the immune response. The 85.7% ORR suggests that combination is doing something the standard triplet has not managed. The absence of progressive disease across all seven evaluable patients, and the observation of deepening response over time rather than plateau, points toward durability rather than a transient radiographic artifact.
Design context is critical before extrapolating. Part 1 of CONVERGE is a feasibility and early efficacy read, not a powered comparison. Intratumoral and intranodal injection in stage III NSCLC is technically demanding — the presentation confirms it is feasible and safe, which clears a non-trivial procedural hurdle for this patient population. The randomized structure of the broader trial means Part 2 will eventually generate a controlled comparison against cCRT plus durvalumab alone, which is where the claim has to stand or fall. NANORAY-312, the Phase 3 study in head and neck cancer, remains the program’s regulatory anchor; CONVERGE is expanding the addressable indication but is not yet the pivotal data set.
The single marker to track now is the complete response rate in the randomized Part 2 cohort. If that rate holds even partially above the sub-5% historical benchmark in a controlled comparison, the regulatory and clinical calculus for stage III NSCLC changes in a meaningful and durable way.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
